<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589340</url>
  </required_header>
  <id_info>
    <org_study_id>11875</org_study_id>
    <nct_id>NCT02589340</nct_id>
  </id_info>
  <brief_title>Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia</brief_title>
  <acronym>BUS-PD</acronym>
  <official_title>Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Portland VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of buspirone in combination&#xD;
      with amantadine in reducing levodopa-induced dyskinesia (LID) in patients with Parkinson's&#xD;
      disease (PD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Plan: We will perform a randomized, placebo-controlled, double-blind, two-period cross-over&#xD;
      study to evaluate the safety, tolerability, and efficacy of a novel treatment combination for&#xD;
      LID in PD.&#xD;
&#xD;
      Methods: Eligible subjects who consent to participate in this study will be randomized to one&#xD;
      of two sequences of treatment interventions during the baseline visit. Each treatment&#xD;
      sequence includes placebo and buspirone interventions. After randomization, each participant&#xD;
      will titrate up on study drug for two weeks ending in 30 mg/day. At the end of each two week&#xD;
      study drug period, the participant will then have a study visit at the VA Portland Health&#xD;
      Care System that includes safety monitoring, adverse event monitoring, drug compliance, and&#xD;
      several measurements of LID.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment&#xD;
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">February 23, 2021</completion_date>
  <primary_completion_date type="Actual">February 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve - Dyskinesia - Forceplate</measure>
    <time_frame>6 hour levodopa dose cycle</time_frame>
    <description>forceplate measurements of levodopa induced dyskinesia taken every 1/2 hour for 6 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dyskinesia - UDysRS</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>UDysRS total score comparison</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>Adverse Events Monitoring/Frequency</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Dyskinesias</condition>
  <condition>Movement Disorders</condition>
  <arm_group>
    <arm_group_label>Buspirone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two week titration up to 10 mg tablet/3 times a day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two week titration up to 3 tablets/3 times a day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone</intervention_name>
    <arm_group_label>Buspirone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar Pill</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Parkinson's disease diagnosis&#xD;
&#xD;
          -  Currently taking a levodopa containing medication for Parkinson's disease&#xD;
&#xD;
          -  Mild to Severe dyskinesia&#xD;
&#xD;
          -  Currently taking between 200-500 mg of amantadine daily for treatment of&#xD;
             levodopa-induced dyskinesia with insufficient suppression levodopa-induced dyskinesia.&#xD;
&#xD;
          -  Stable medication regimen for at least 4 weeks prior to study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving any other treatment for levodopa-induced dyskinesia, including but&#xD;
             not exclusive to deep brain stimulation.&#xD;
&#xD;
          -  Not able to follow verbal commands&#xD;
&#xD;
          -  Not able to stand unsupported for at least 60 seconds&#xD;
&#xD;
          -  Not able to answer a patient questionnaire about their symptoms of Parkinson's disease&#xD;
             and dyskinesia.&#xD;
&#xD;
          -  Have proprioceptive deficits.&#xD;
&#xD;
          -  Have a history of hepatic impairment&#xD;
&#xD;
          -  Currently have severe renal impairment&#xD;
&#xD;
          -  Currently have any other medical or psychiatric diagnosis that would preclude their&#xD;
             ability to safely participate in the study.&#xD;
&#xD;
          -  Significant cognitive impairment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breast-Feeding&#xD;
&#xD;
          -  Unable to swallow study drug (capsule)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VA Portland Health Care System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Kathryn Anne Chung</investigator_full_name>
    <investigator_title>Associate Professor - Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

